Evidence map›Paper›PMID 37223853›Full record

ReviewCurrent atherosclerosis reports2023

In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?

Mario Enrico Canonico, Connie N Hess, Christopher P Cannon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mario Enrico CanonicoCPC Clinical Research, 2115 N Scranton Street #2040, Aurora, CO, 80045-7120, USA. marioenrico.canonico@cpcmed.org.ORCID 0000-0001-8452-7464
Connie N HessCPC Clinical Research, 2115 N Scranton Street #2040, Aurora, CO, 80045-7120, USA.
Christopher P CannonCPC Clinical Research, 2115 N Scranton Street #2040, Aurora, CO, 80045-7120, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to analyze and discuss the most recent data on in hospital prescription of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors in patients with acute coronary syndrome (ACS). RECENT

findingsRecent randomized clinical trials (RTCs) have demonstrated a beneficial effect of monoclonal antibodies (mAb) PCSK9i prescription in patients with ACS on rapid reduction of low-density lipoprotein cholesterol (LDL-C) and on coronary atherosclerosis assessed by intracoronary imaging. Additionally, the safety profile of mAb PCSK9i was confirmed in all RTCs. Available RCTs show the effectiveness and rapid achievement of LDL-C levels according to American College of Cardiology/American Heart Association and European Society of Cardiology guidelines for ACS patients. However, RCTs addressing cardiovascular outcomes of PCSK9i in-hospital initiation in ACS patients are currently ongoing.

Indexed as

Acute Coronary SyndromeAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAntibodies, MonoclonalCholesterol, LDLHumansPCSK9 InhibitorsProprotein Convertase 9Proprotein ConvertasesSubtilisinUnited StatesAntibodies, MonoclonalAnticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Proprotein ConvertasesSubtilisinAcute coronary syndromeLipid lowering therapyMajor adverse cardiovascular eventsPCSK9i

Identifiers

PMID37223853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.